SYNTARA LIMITED (SNT)
Share Price Analysis and Chart

04/05/2026

1

Buy

$0.06

114.29%

Syntara has reached alignment with the FDA on the Phase 2b trial design for amsulostat in myelofibrosis. Bell Potter believes this removes a key overhang and clears the path to commence the study, with topline data expected in 2029.

The broker highlights the outcome as a clear positive, while noting an $8-10m capital raise extends funding to 3Q2027, although additional capital will be required to fully fund the Phase 2b program.

Bell Potter views Amsulostat as remaining positioned as a potentially attractive asset in a sizeable and competitive myelofibrosis market currently dominated by JAK inhibitors.

No material forecast changes are made, and the broker maintains a 6c target and a Speculative Buy rating.

FORECAST
Bell Potter forecasts a full year FY26 EPS of minus -0.60 cents.
Bell Potter forecasts a full year FY27 EPS of minus -0.50 cents.

01/12/2025

1

Buy

$0.19

578.57%

Syntara provided an update on its early topical scar programs SNT-6302 and SNT-9465, which Canaccord Genuity finds "intriguing."

The broker is still valuing the assets at zero, given early data and unclear reimbursement and despite promising trial/imaging advances. 

If mid-2026 results are IND (investigational new drug)-enabling, the broker sees that as the right point to reassess. This would likely be in the context of a licensing or partnering deal since the company probably won’t advance development alone.

Buy. Target unchanged at 19c.